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Abstract
Background: Since 2002 the sick funds in Germany have widely implemented disease management
programs (DMPs) for patients with type 2 diabetes mellitus (DM) and coronary heart disease (CHD). Little
is known about the characteristics, treatment and target attainment lipid levels of these patients enrolled
in DMPs compared to patients in routine care (non-DMP).
Methods: In an open, non-interventional registry (LUTZ) in Germany, 6551 physicians documented
15,211 patients with DM (10,110 in DMP, 5101 in routine care) and 14,222 (6259 in DMP, 7963 in routine
care) over a follow-up period of 4 months. They received the NCEP ATP III guidelines as a reminder on
lipid level targets.
Results: While demographic characteristics of DMP patients were similar to routine care patients, the
former had higher rates of almost all cardiovascular comorbidities. Patients in DMPs received
pharmacological treatment (in almost all drug classes) more often than non-DMP patients (e.g.
antiplatelets: in DM 27.0% vs 23.8%; in CHD 63.0% vs. 53.6%). The same applied for educational measures
(on life style changes and diet etc.). The rate of target level attainment for low density lipoprotein
cholesterol (LDL-C) < 100 mg/dl was somewhat higher in DMP patients at inclusion compared to non-
DMP patients (DM: 23.9% vs. 21.3%; CHD: 30.6% vs. 23.8%) and increased after 4 months (DM: 38.3% vs.
36.9%; CHD: 49.8% vs. 43.3%). Individual LDL-C target level attainment rates as assessed by the treating
physicians were higher (at 4 months in DM: 59.6% vs. 56.5%; CHD: 49.8% vs 43.3%). Mean blood pressure
(BP) and HbA1c values were slightly lowered during follow-up, without substantial differences between
DMP and non-DMP patients.
Conclusion: Patients with DM, and (to a greater extent) with CHD in DMPs compared to non-DMP
patients in routine care have a higher burden of comorbidities, but also receive more intensive
pharmacological treatment and educational measures. The present data support that the substantial
additional efforts in DMPs aimed at improving outcomes resulted in quality gains for achieving target LDL-
C levels, but not for BP or HbA1c. Longer-term follow-up is needed to substantiate these results.
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Background
Disease management typically refers to multidisciplinary
efforts to improve the quality and cost-effectiveness of
care for selected patients suffering from chronic condi-
tions [1]. An explicit systematic population-based
approach is applied to identify persons at risk, to inter-
vene with specific programs of care (disease management
programs, DMP), and to measure clinical and other out-
comes [2]. These programs, however, are widely heteroge-
neous across health-care systems, and difficult to compare
across interventions [3]. In the German statutory health
insurance in 2002 some of the worlds largest DMPs  with-
out a pilot evaluation phase  were launched, initially for
type 2 diabetes mellitus (DM), breast cancer and coronary
heart disease (CHD), subsequently also for type 1 DM and
asthma/COPD [4,5]. The nationwide DMPs have been
implemented through sick funds, which cover around
88% of the general population, and to date, 14,000 of
such programs have been accredited [6]. Physicians that
enrol voluntarily in such programs are legally obliged to
follow certain evidence-based clinical practice guidelines
and to document individual patients comprehensively. As
an incentive, sick funds receive a higher remuneration for
DMP patients from the risk structure compensation pool
and the patient can expect to be provided with higher-
quality and more cost-effective care [4].
While sick funds are obliged by law to intermittently carry
out DMP evaluations, such procedures are performed
without a control group, are strictly limited to the accred-
itation period and to a relative lean core data set [7]. Cri-
teria for evaluation include medical issues, economic
issues and quality of life. Until now, not much is known
about data quality or outcomes [8]. While according to
the German Ministry of Health analyses up to 2005 gen-
erally indicate good patient management [9], the Federal
Physician Association (Kassenärztliche Bundesvereini-
gung) stated that there is a substantial need for additional
funding for guideline-oriented therapy [10].
DMPs for DM and/or CHD consider lipid lowering ther-
apy to be an integral part of the treatment [7]. Low-density
lipoprotein cholesterol (LDL-C) is acknowledged as a piv-
otal parameter for assessment of the success of lipid-low-
ering therapy, and patients with DM or CHD have a
common target goal of < 100 mg/dl [11]. Therefore, this
LDL-C threshold can be used for a joint evaluation for
both patient groups. Further, target level attainment rates
of blood pressure or HbA1c targets lend themselves for
outcomes research.
The present registry in the primary care setting aimed to
address the following questions: (1) Do patients in DMPs,
separated by indication (DM and CHD) differ from
patients not treated in DMPs (routine care) in terms of
demographic characteristics, comorbidities/risk factors, or
treatment? (2) Can during a follow-up period of 4
months, by participation in the registry and dissemina-
tion of guidelines, treatment be quantitatively and quali-
tatively improved? (3) Are LDL-C, blood pressure and
glycosylated haemoglobin A1c (HbA1c) target level attain-
ment rates higher in patients within DMPs compared to
patients in routine care (non-DMP)? (4) Do target level
attainment rates differ between the DMPs for DM and
CHD?
Methods
Study design and patients
The present study (Lipidmanagement und Therapieziel-
Erreichung bei Patienten mit KHK und/oder Diabetes
mellitus, LUTZ) was designed as a prospective observa-
tional, non-interventional, multicentre registry at 6551
sites throughout Germany, and performed between
March 2006 and April 2007. Practice-based family physi-
cians and internists (serving as general physicians, or hav-
ing a speciality in diabetology or cardiology) were invited
to participate, irrespective of whether they took part in
DMPs or not.
In addition to the case report forms (CRFs), physicians
were informed about authoritative guidelines concerning
LDL-C target levels for patients with CHD and/or DM,
respectively. They received a printed summery of the
updated National Cholesterol Education Panel Adult
Panel III (NCEP ATP III) guidelines [11].
They were requested to include 6 male or female outpa-
tients with CHD and/or DM. In practices that participated
in a DMP, this sample was to be balanced (3 patients in
any DMP, 3 non-DMP patients). Further, physicians had
to ensure that after study initiation the next 6 eligible
patients had to be documented sequentially to avoid
selection bias. Patients had to have hypercholesterolae-
mia as diagnosed by the treating physician, a history of
CHD and/or DM, and should be on chronic treatment
with a statin at inclusion. No other inclusion or exclusion
criteria applied.
The study was approved by the certified ethics committee
of the Bavarian Physicians Chamber. Patient data protec-
tion was fully ensured. As part of the quality assurance
process, an on-site audit was performed in 50 centres. For
the complete documentation of each patient, physicians
received a small remuneration of 20 n per patient, which
is standard for this type of study.
Physician characteristics
In connection with the agreement form, physicians were
requested to report their year of birth, gender, and start
date of practice-based service. Further, they noted whetherBMC Public Health 2009, 9:280 http://www.biomedcentral.com/1471-2458/9/280
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they practised in a rural area, a small or large town, and
the number of patients per quarter, the number of physi-
cian colleagues in their practice, the participation of their
practice in one or more of the DMPs, and the number of
patients in the DMPs for CHD or DM (if applicable).
Assessments
Two visits were foreseen (baseline and 4-month follow
up). At entry, physicians recorded patient characteristics
(weight, height), demographic data (year of birth, gen-
der), inclusion in the DMPs for CHD or DM (if applica-
ble), and the inclusion diagnosis (CHD, DM). Further,
they documented cardiac risk factors (CHD with details
on type of manifestation or intervention, e.g. myocardial
infarction, atrial fibrillation or symptomatic arrhythmias,
heart failure, positive cardiac family history for CHD), cer-
ebrovascular disease (transient ischaemic attack, pro-
longed ischaemic neurological deficit, and stroke), renal
insufficiency, other risk factors (hypercholesterolaemia,
arterial hypertension, smoking, microalbuminuria). If
applicable, general information on educational measures
for patients about DM (on lifestyle changes and diet),
coagulation (vitamin K antagonists), arterial hypertension
or other, were noted.
Current therapy was recorded for beta-blockers, antiplate-
lets, nitrates, ACE inhibitors, calcium antagonists, oral
antidiabetic drugs, and insulin. Lipid-lowering drugs were
recorded, with particular focus on statins (simvastatin,
lovastatin, fluvastatin, pravastatin, atorvastatin) with the
respective dosages (10, 20, 40, 80 mg/d). Further, the cho-
lesterol absorption inhibitor ezetimibe, fibrates, nicotinic
acid derivatives and bile acid sequestrants were recorded.
The results of the current treatment were noted for hyper-
lipidaemia (laboratory values for total cholesterol, LDL-C,
high density lipoprotein cholesterol (HDL-C), and triglyc-
erides), for hypertension (systolic and diastolic blood
pressure), and long-term glycaemia status (HbA1c). Physi-
cians commented on whether, according to their judge-
ment, LDL-C target levels were attained ("individual
targets").
At about 4 months, drug therapy and results were
recorded in an analogous manner as at entry. Apart from
these data, no further information about efficacy and
safety was collected. If an adverse drug reaction occurred,
physicians were requested to notify the manufacturer of
the drug associated with the event.
Data management and statistics
Data were stored with the database system Microsoft
Access 2003, and analysed with the statistical program
SAS release 8.2. (SAS Institute Inc., Cary, NC, USA). For
quality assurance, plausibility checks using minimum and
maximum values for the individual parameters were
applied. Descriptive statistics were calculated and distri-
bution of parameters was presented as means with stand-
ard deviation. Data are presented by indication (DM vs.
CHD) and by DMP versus non-DMP groups, respectively.
Statistical comparisons were performed between patients
in the DMP vs. non-DMP groups within the two indica-
tions (statistical significance was set at the 0.05 level). For
this descriptive analysis, corrections for multiple compar-
isons were not performed.
Results
Physician characteristics
The majority of investigators (n = 6551) were general/
family physicians (72.2%) or internists (30.1%). A spe-
cialisation in diabetology was reported in 3.9%, and in
cardiology in 1.8%. Most physicians (60.8%) worked
alone, and 36.4% in various cooperation forms with col-
leagues (2.8% not reported). Of the physicians, 24.7%
saw  1500 patients/quarter with insurance in sick funds,
36.8% between 1000 and 1500, and 26.2% fewer than
1000.
The large majority of physicians (93.1%) took part in a
DMP: 25.7% unspecified, 61.6% in both DMPs for CHD
and DM, 10.3% for DM alone, and 2.5% for CHD alone.
Practices that did not participate in any DMP accounted
for 6.7% (0.2% not reported).
Patient characteristics and comorbidities at entry
A total of 45,873 patients were documented in the regis-
try. Patients with private insurance (n = 3047), those with-
out information on DMP status (n = 747), patients who
participated in both DMP programs concomitantly (n =
8233 patients), and those with no inclusion diagnosis (n
= 4630) were not considered for this analysis.
Figure 1 displays the distribution of patients by indication
and by their participation in one of the DMPs. While two
thirds of DM patients were registered in respective DMP,
less than half of CHD patients were.
Table 1 shows the demographic characteristics of patients
at baseline. As expected, concomitant diseases and risk
factors were frequent in patients with DM as well as CHD.
No important differences were noted with regards to age,
gender distribution, and body mass index between DMP
and non-DMP patients. However, with regards to con-
comitant diseases, the DM DMP patients had a higher rate
of comorbidities for almost all concomitant diseases. In
the CHD indication, for DMP patients there was a sub-
stantial higher proportion of patients with post myocar-
dial infarction or coronary artery bypass graft, while the
non-cardiac comorbidities did not differ relevantly
between DMP and non-DMP patients (Table 1 bottom).BMC Public Health 2009, 9:280 http://www.biomedcentral.com/1471-2458/9/280
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Educational measures and drug therapy
In the DM indication, DMP patients compared to non-
DMP patients received more frequently educational meas-
ures for lifestyle and diet (75.6% vs. 40.7%) or hyperten-
sion (12.0% vs. 7.4%). Regarding CHD, a similar finding
was noted for educational measures on hypertension
(27.0% vs. 14.0%).
Table 2 summarises the disease-specific drug therapy at
inclusion at 4 months. With declining frequency, statins,
beta-blockers, and ACE inhibitors were the most fre-
quently named classes. Regarding DM, in DMP patients
all cardiac and antidiabetic medications were more fre-
quently reported in DMP compared to non-DMP patients,
but no major differences were noted for lipid lowering
medications. Similarly, regarding CHD, all drug classes
were at least numerically more frequent in DMP patients
(with the exception of fibrates), but the differences for
lipid lowering medications were generally small (for
example statins in CHD: 81.4% vs. 79.4%). The most fre-
quently prescribed agent was simvastatin. The 20 mg and
40 mg daily dose were preferably used for all statins. Nota-
bly, only about a quarter of DM patients were prescribed
antiplatelets, in contract to three quarters of CHD
patients.
At 4 months, the rate of patients with a statin/ezetimibe
combination therapy increased, whereas treatment rates
with respect to almost all other drug classes decreased
slightly.
Target level attainment
Lipids
At entry, mean LDL-C values were significantly lower in
DMP patients in DMPs compared to patients in routine
care (DM: 130 mg/dl vs. 134 mg/dl; CHD: 122 mg/dl vs.
132 mg/dl). At entry, LDL-C target level attainment (< 100
mg/dl) was generally low, however, higher rates in DMP
patients were noted compared to non-DMP patients with
a much larger difference in CHD patients (DM: 23.9% vs.
21.3%; CHD: 30.6% vs. 23.8%; Table 3).
After 4 months, rates had improved substantially in DMP
patients and non-DMP patients (DM: 38.3% vs 36.9%;
CHD: 49.8% vs. 43.3%). Notably, investigator's ratings of
individual LDL-C target level attainment rates were sub-
stantially higher in all groups.
Mean total cholesterol and triglyceride values decreased
substantially, while HDL-C values increased slightly both
in DMP and non-DMP patients (in DM and CHD).
CHD, coronary heart disease; DM-2, type 2 diabetes mellitus; DMP, disease management program Figure 1
CHD, coronary heart disease; DM-2, type 2 diabetes mellitus; DMP, disease management program. Results of 
patients in shadowed fields are described in detail in the tables of this paper. Note that results of patients who participated in 
both DMPs concomitantly (n = 8233) are not described in the present article.
LUTZ registry
n= 45.873
Sick funds
n= 42.079
Private insurance
n= 3.047
DM 
n=15.453
CHD
n=14.510
DM + CHD
n= 8.233
No inclusion diagnosis
n= 4.630
DM in DMP
n= 10.110
DM not in DMP
n= 5.101
Unknown
n= 242
CHD in DMP
n= 6.259
CHD not in DMP
n= 7.963
Unknown
n= 288
No information
on insurance n= 747BMC Public Health 2009, 9:280 http://www.biomedcentral.com/1471-2458/9/280
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Table 1: Demographics, comorbidities and cardiovascular risk factors, by indication and DMP participation, respectively
DM in DMP DM not in DMP
Parameter Value n/N Value n/N p-value
Mean ± SD 10110 Mean ± SD 5101
Age (years)
All 62.1 ± 11.4 62.4 ± 11.8 0.1
Male 60.8 ± 11.0 60.5 ± 11.3 <0.0001
Female 63.6 ± 11.7 64.4 ± 11.9 <0.0001
BMI (kg/m2)
All 30.1 ± 5.2 29.6 ± 5.0 <0.0001
Male 29.8 ± 4.8 29.4 ± 4.6 <0.05
Female 30.5 ± 5.6 29.8 ± 5.4 <0.05
Cardiovascular risk factors % %
Hypercholesterolemia 88.3 (8932/10110) 88.7 (4525/5101) 0.51
Hypertension 83.5 (8445/10110) 78.5 (4002/5101) <0.0001
Current smoker 17.5 (1774/10110) 19.8 (1011/5101) <0.001
Positive family history for CHD 24.3 (2456/10110) 21.8 (1110/5101) <0.001
Comorbidity % %
Angina pectoris 7.7 (779/10110) 5.5 (280/15101) <0.0001
Myocardial infarction 6.4 (652/10110) 3.6 (184/5101) <0.0001
Coronary artery bypass graft (CABG) 3.7 (370/10110) 1.6 (83/5101) <0.0001
Cardiac insufficiency 9.4 (955/10110) 9.2 (469/5101) 0.61
Atrial fibrillation cardiac arrhythmia 6.3 (633/10110) 5.4 (275/5101) <0.05
Renal insufficiency 7.7 (774/10110) 6.9 (352/5101) 0.09
Microalbuminuria 16.1 (1630/10110) 13.0 (662/5101) <0.0001
Peripheral arterial disease (PAD) 7.9 (796/10110) 6.7 (340/5101) 0.01
Peripheral amputation due to PAD 1.1 (111/10110) 1.1 (54/5101) 0.83
Stroke/transient ischemic ischemia 6.7 (682/10110) 6.4 (327/5101) 0.43
CHD in DMP CHD not in DMPBMC Public Health 2009, 9:280 http://www.biomedcentral.com/1471-2458/9/280
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Parameter Value n/N Value n/N p-value
Mean ± SD 6259 7963
Age (years)
All 62.6 ± 11.5 63.7 ± 11.5 <0.0001
Male 62.0 ± 10.9 62.4 ± 11.2 <0.0001
Female 63.8 ± 12.5 65.8 ± 11.7 <0.0001
BMI (kg/m2)
All 27.5 ± 3.8 27.6 ± 3.9 0.74
Male 27.6 ± 3.6 27.6 ± 3.7 <0.001
Female 27.3 ± 4.3 27.4 ± 4.2 <0.001
Cardiovascular risk factors % %
Hypercholesterolemia 92.0 (5760/6259) 92.4 (7355/7963) 0.46
Hypertension 83.7 (5236/6259) 81.4 (6483/7963) <0.001
Current smoker 22.3 (1393/6259) 24.9 (1983/7963) <0.001
Positive family history for CHD 39.2 (2452/6259) 40.0 (3184/7963) 0.33
Comorbidity % %
Angina pectoris 31.3 (1960/6259) 31.2 (2493/7963) 0.86
Myocardial infarction 54.1 (3384/6259) 37.5 (2984/7963) <0.0001
Coronary artery bypass graft (CABG) 31.9 (1994/6259) 21.8 (1734/7963) <0.0001
Cardiac insufficiency 14.7 (917/6259) 13.2 (1051/7963) <0.05
Atrial fibrillation cardiac arrhythmia 11.1 (697/6259) 11.8 (943/7963) 0.19
Renal insufficiency 5.0 (310/6259) 4.7 (378/7963) 0.57
Microalbuminuria 2.6 (164/6259) 2.3 (186/7963) 0.28
Peripheral arterial disease (PAD) 7.7 (483/6259) 8.0 (640/7963) 0.48
Peripheral amputation due to PAD 0.2 (15/6259) 0.3 (25/7963) 0.41
Stroke/transient ischemic ischemia 5.1 (318/6259) 6.6 (527/7963) <0.001
DMP, Disease Management Program; SD, standard deviation; DM, diabetes mellitus; CHD, coronary heart disease. n, number of documented 
patients; N, all patients in the group. Difference to 100%: value not reported. * p-values refer to difference between patient in DMP and not in DMP 
(routine care) in the respective indication.
Table 1: Demographics, comorbidities and cardiovascular risk factors, by indication and DMP participation, respectively (Continued)BMC Public Health 2009, 9:280 http://www.biomedcentral.com/1471-2458/9/280
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Table 2: Diagnosis specific medication at inclusion and after 4 months
Parameter Type-2 Diabetes Mellitus
DM in DMP
n = 10110
DM not in DMP
n = 5101
Inclusion After 4 months Inclusion After 4 months p-value*
Drug class/agent %%%%
Beta blocker 42.8 41.2 40.1 39.8 <0.01
Antiplatelet 27.0 26.7 23.8 23.3 <0.0001
Nitrate 5.5 5.5 4.0 4.0 <0.0001
ACE inhibitor 61.3 58.5 55.5 52.8 <0.0001
Calcium antagonist 23.8 23.0 21.3 19.9 <0.001
Oral antidiabetic drug 67.8 62.2 63.9 58.9 <0.0001
Insulin 31.9 29.9 22.8 20.8 <0.0001
Statin monotherapy 77.5 57.7 76.8 57.0 0.3
Simvastatin 53.5 38.3 52.5 36.7 0.27
Lovastatin 2.2 1.3 2.8 1.6 <0.05
Pravastatin 9.2 5.5 8.7 5.7 0.3
Fluvastatin 5.2 3.8 4.8 3.7 0.38
Atorvastatin 3.3 1.8 3.3 1.9 0.92
Ezemtimibe+ statin combination 12.0 31.0 12.2 31.3 0.79
Ezetimibe monotherapy 1.6 2.4 1.8 2.6 0.39
Fibrates 3.0 2.2 2.8 2.1 0.48
Nicotinic acid derivates 0.5 0.5 0.3 0.5 0.12
Anionic-exchange resins 0.0 0.0 0.1 0.1 0.19
Parameter Coronary Heart Disease
CHD in DMP
n = 6259
CHD not in DMP
n = 7963
Inclusion After 4 months Inclusion After 4 months p-value*
Drug class/agent %%%%BMC Public Health 2009, 9:280 http://www.biomedcentral.com/1471-2458/9/280
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Blood pressure and HbA1c
Compared to baseline values, mean systolic/diastolic
blood pressure were slightly lower after 4 months, with no
substantial differences between DMP and non-DMP
patients (Table 3 bottom). Likewise, in diabetic patients
mean HbA1c decreased slightly from a baseline level of
7.1% to 6.9%.
Discussion
Characteristics and comorbidities
The present registry documents a large current sample of
primary care patients with type 2 DM or CHD, managed
in the context of DMPs or in routine care (non-DMP).
While patients in the respective DMPs did not differ
remarkably in terms of demographic characteristics (age,
gender, BMI), they did with regards to comorbidities
(which were generally more frequent in DMP patients).
The present data do not confirm the concern that in the
DMPs the relatively young and healthy diabetics would be
enrolled rather than the targeted high-risk population
[12]. A substantial difference between DMP and non-
DMP patients was for the former group the higher partic-
ipation rate in patient education programs, which can be
attributed, among other factors, to the explicit recommen-
dations stated in the DMP guidelines. It was in the same
order for DM (but lower for CHD) when compared to a
nationwide cross-sectional survey of primary care in Ger-
many in 2003, which reported a rate of 65.0% for diet
counselling, dietary education, or physical activity educa-
tion programs for DM patients versus 52.5% for CHD
patients [13].
Treatment and target level attainment
In terms of treatment, DMP patients (DM and CHD) had
higher drug prescription rates than non-DMP patients,
which may reflect higher treatment intensity, but may also
Beta blocker 81.7 76.5 71.6 67.6 <0.0001
Antiplatelet 63.0 58.5 53.6 49.5 <0.0001
Nitrate 24.2 22.0 18.6 16.9 <0.0001
ACE inhibitor 68.1 64.4 64.1 60.0 <0.0001
Calcium antagonist 20.9 19.6 20.6 19.3 0.67
Oral antidiabetic drug 3.2 4.6 2.4 3.5 <0.01
Insulin 1.1 1.2 0.9 0.9 0.4
Statin monotherapy 81.4 57.9 79.4 53.3 <0.01
Simvastatin 52.4 35.7 48.6 31.3 <0.0001
Lovastatin 2.3 1.3 2.2 1.5 0.75
Pravastatin 9.5 5.7 10.4 5.8 0.09
Fluvastatin 6.5 4.4 6.4 4.0 0.86
Atorvastatin 6.5 3.9 7.0 3.8 0.28
Ezemtimibe+ statin combination 17.2 37.4 16.8 41.2 0.6
Ezetimibe monotherapy 3.1 4.0 3.0 3.5 0.84
Fibrates 1.1 0.8 1.6 1.0 <0.05
Nicotinic acid derivates 0.6 0.6 0.6 0.7 0.99
Anionic-exchange resins 0.1 0.1 0.1 0.1 0.81
Values are mean ± SD or percentages, respectively. ACE inhibitor, angiotensin converting enzyme inhibitor.
*p-values refer to difference between patient in DMP and not in DMP (routine care) in the respective indication at inclusion.
Table 2: Diagnosis specific medication at inclusion and after 4 months (Continued)BMC Public Health 2009, 9:280 http://www.biomedcentral.com/1471-2458/9/280
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Table 3: Lipids, HbA1c and blood pressure: values and target level attainment at inclusion and after 4 months
Parameter Type-2 Diabetes Mellitus
DM in DMP
n = 10110
DM not in DMP
n = 5101
p-value*
Lipids Inclusion After 4 months Inclusion After 4 months
LDL-C; mg/dl (mean ± SD) 129.5 ± 38.9 111.9 ± 30.4 133.5 ± 40.4 113.5 ± 31.1 <0.0001
LDL-C < 100 mg/dl 23.9% 38.3% 21.3% 36.9% <0.01
LDL-C target level attained** 46.5% 59.6% 35.0% 56.5% <0.0001
LDL-C target level not attained** 48.9% 30.9% 59.5% 32.4% <0.001
Total cholesterol, mg/dl (mean ± SD) 218.1 ± 50.5 195.5 ± 38.7 223.8 ± 52.2 198.0 ± 39.5 <0.0001
HDL-C, mg/dl (mean ± SD) 51.2 ± 13.3 52.4 ± 12.8 51.0 ± 13.2 52.3 ± 12.6 0.49
Triglycerides, mg/dl
(mean ± SD)
199.7 ± 96.7 179.5 ± 82.4 201.6 ± 95.9 181.7 ± 84.5 0.11
Blood glucose
HbA1c, % (mean ± SD) 7.1 ± 1.1 6.9 ± 1.0 7.1 ± 1.2 6.8 ± 1.0 <0.001
Blood pressure, mmHg
Systolic (mean ± SD) 138.1 ± 14.9 134.7 ± 13.4 138.8 ± 15.0 134.8 ± 13.4 <0.05
Diastolic (mean ± SD) 81.3 ± 8.5 79.9 ± 7.8 81.8 ± 8.7 80.3 ± 7.8 <0.001
Parameter Coronary Heart Disease
CHD in DMP
n = 6259
CHD not in DMP
n = 7963
p-value*
Lipids Inclusion After 4 months Inclusion After 4 months
LDL-C; mg/dl (mean ± SD) 122.1 ± 38.0 104.6 ± 27.7 131.6 ± 41.7 109.7 ± 30.9 <0.0001
LDL-C < 100 mg/dl 30.6% 49.8% 23.8% 43.3% <0.0001
LDL-C target level attained** 42.4% 65.7% 34.5% 60.6% <0.0001
LDL-C target level not attained** 53.8% 25.7% 61.8% 30.2% <0.0001
Total cholesterol, mg/dl (mean ± SD) 206.5 ± 48.7 184.8 ± 35.8 219.9 ± 54.0 192.7 ± 39.6 <0.0001BMC Public Health 2009, 9:280 http://www.biomedcentral.com/1471-2458/9/280
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correspond to the higher rates of comorbidities. For CHD
patients in DMPs a similar finding has been reported from
the ELSID study [14]. It has in fact been shown that in DM
patients treatment intensity is generally increased after
complications have occurred, i.e. at a later stage in the dis-
ease process [15]. While treatment rates with antiplatelet
drugs were higher in DMP patients, they were not satisfac-
tory in any subgroup, as patients with CHD and those
with DM (as a coronary equivalent) are at high risk of a
recurrent or first cardiovascular event and should receive
such drugs [16,17].
A focus of this registry was on the treatment with lipid-
lowering drugs. The NCEP ATP III guidelines re-empha-
sised the importance of lowering elevated levels of LDL-C
as the most efficacious treatment to reduce the incidence
of CHD mortality and morbidity [11,18]. For every 30
mg/dl change in LDL-C the relative risk for the incidence
of coronary artery disease (CAD) changes by 30% [11].
Consequently, for patients with a high cardiovascular risk
(e.g. with manifest CHD or DM) a LDL-C target of < 100
mg/dl (2.6 mmol/l) should be reached, and in patients
with very high CHD risk, optionally < 70 mg/dl [11]. The
present registry shows that a high percentage of patients,
irrespective of inclusion in DMPs, do not attain these lipid
targets. This is in line with reports from earlier registries in
Germany, for example the DUTY registry (2002) in
59,035 patients with DM (LDL-C target attainment rate <
100 mg/dl 16.6% at the end of observation) [19], the 4E
registry (2001/2002) in the subgroup of 12,816 patients
with DM in primary or secondary CHD prevention (LDL-
C target attainment rates < 100 mg/dl 16% in men, 12%
in women) [20], and the 2L cardio registry in high-risk or
very-high-risk patients (37.1% < 100 mg/) [21]. No effec-
tiveness data on the lipid management are available in the
context of DMPs in Germany to date, but reports from the
US in the managed care environment show that the situa-
tion is similarly suboptimal [22-24]. It must be noted that
in the German DMPs for CHD the target value for LDL-C
is set at 100 mg/dl, while in the DMPs for DM, lipid-low-
ering therapy is recommended, but no target value pro-
vided [4]. This may provide one explanation, why in this
registry the LDL-C target attainment in patients in the
CHD DMP was slightly higher (at entry and follow-up)
than in those in the DM DMP. Another explanation is that
patients with manifest CHD are more likely to be strin-
gently treated than those with a coronary risk equivalent
"only".
Patients irrespective of inclusion in the DMPs improved
with regard to their lipid status during the follow-up in
our registry. The effect was substantial, as through intensi-
fication of therapy an additional LDL-C decrease of 21
mg/dl was achieved. Of note, the rates of combination
therapy with statins plus ezetimibe increased substan-
tially. NCEP ATP III describe various options to achieve
stringent lipid targets, among them high doses of statins,
but also various combination approaches of statins with
ezetimibe, fibrates, bile acid sequestrants, or nicotinic
acid, under consideration to safety of the regimen for the
individual patient as well as to efficacy of treatment [11].
It has repeatedly been reported that physicians are reluc-
tant to increase statin doses, for example in the managed
care environment where titration was noted in only 3%
[25], or in other settings [26,27]. Our registry data were in
line with these findings, as mean doses of the various stat-
ins were in the lower range of the labelled range, were
only slightly increased during the follow-up, and the full
HDL-C, mg/dl (mean ± SD) 51.4 ± 12.8 52.3 ± 12.3 52.4 ± 13.7 53.6 ± 13.1 <0.01
Triglycerides, mg/dl
(mean ± SD)
170.9 ± 85.1 156.7 ± 72.1 178.1 ± 87.8 160.0 ± 74.1 <0.0001
Blood glucose
HbA1c, % (mean ± SD) 6.2 ± 0.9 6.2 ± 0.8 6.1 ± 0.9 6.1 ± 0.8 0.09
Blood pressure, mmHg
Systolic (mean ± SD) 132.6 ± 14.6 130.3 ± 12.9 135.2 ± 15.1 131.8 ± 12.7 <0.0001
Diastolic (mean ± SD) 79.6 ± 8.3 78.7 ± 7.7 80.9 ± 8.6 79.6 ± 7.6 <0.0001
* p-values refer to difference between DMP and non-DMP patients in the respective indication at inclusion
** according to physician assessment (not according to guidelines)
Table 3: Lipids, HbA1c and blood pressure: values and target level attainment at inclusion and after 4 months (Continued)BMC Public Health 2009, 9:280 http://www.biomedcentral.com/1471-2458/9/280
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80 mg doses were rarely prescribed. The reluctance to pre-
scribe statins in high doses may be due to the fear of
increased side effects [28].
Mean BP and HbA1c during the 4-month follow-up were
only slightly modified, which hints at the need of further
treatment intensification. The HYDRA study in 2003 has
shown that only a marginal proportion (1.3%) of all dia-
betic patients achieves a combined target of LDL < 100
mg/dl, HbA1c < 7% and blood pressure < 135/85 mmHg
[29].
Methodological considerations
A number of methodological considerations deserve
attention. A more optimal design for addressing our
research questions would have been a (cluster-)ran-
domised approach (DMP versus routine care) [14]. Fur-
ther, the sample selection was mainly guided by
hypercholesterolemia as the qualifying diagnosis and stat-
ins as treatment, which is a selection process. Compari-
sons between groups can only be made with caution
(potential confounding by comorbidity), which is a meth-
odological problem applying to all analysis of the results
of DMPs [30]. The distribution of guidelines can to some
extent be regarded to be a form of intervention, since phy-
sicians were informed about the LDL-C targets, which
may well have contributed to the substantial improve-
ment in target level achievement rates, irrespective of the
participation in a DMP. The observation period of 4
months is rather short in view of the long-term manage-
ment that is indicated for these patients, but it shows that
within a short time frame, substantial improvement in
lipid management can be achieved. Even so, in addition
to the surrogate laboratory measures, disease-specific end-
points, in particular cardiovascular outcomes, would be of
great interest [31]. Preliminary data from the first ran-
domised controlled study in 2300 patients enrolled in
diabetes DMPs in 85 primary care offices suggest that
mortality in these patients compared to routine care
patients matched for demographic characteristics and
severity of disease might be reduced [30].
Conclusion
In summary, the present registry shows that patients in
DMPs do not relevantly differ from non-DMP patients
with regards to demographic characteristics, but have a
higher level of comorbidity. DMP patients receive more
intensive drug and non-drug treatment (educational
measures), and have generally more favourable lipid lev-
els and slightly higher target LDL-C attainment rates
(which must be seen in the context of higher baseline
LDL-C values for non-DMP patients). However, for BP
and HbA1c, the participation in DMP has no impact. The
distribution of the NCEP ATP III guidelines as a reminder
on lipid target levels generally appears to be suitable for
improving LDL-C values.
Overall, at the end of the follow-up period, mean LDL-C
target attainment rates in DMP and non-DMP patients
were among the highest reported to date in primary care,
which is an encouraging finding.
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